PODCAST | Product Development
Gene therapy safety concerns, amylin obesity data and FDA’s future — a BioCentury podcast
What the second death of a DMD patient treated with Elevidys means for gene therapy. Amylin’s momentum grows in obesity, and new leadership’s vision for FDA
June 16, 2025 10:47 PM UTC
The tragic death of a second non-ambulatory DMD patient treated with Elevidys gene therapy from Sarepta Therapeutics Inc. (NASDAQ:SRPT) marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new modality. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the opportunity FDA, companies and patient advocates have to share data and identify a safe path forward for the gene therapy field, both in DMD and beyond. ...